W. Brückl

534 total citations
27 papers, 329 citations indexed

About

W. Brückl is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, W. Brückl has authored 27 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in W. Brückl's work include Lung Cancer Treatments and Mutations (17 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Research Studies (6 papers). W. Brückl is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Research Studies (6 papers). W. Brückl collaborates with scholars based in Germany and China. W. Brückl's co-authors include Susanne Merkel, Amanda Tufman, Rudolf M. Huber, Franz Rödel, Kathrin Günther, Hermann Keßler, Wein Aj, W. Hohenberger, Birgit Bittorf and Wolfgang G. Ballhausen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Surgery and Annals of Oncology.

In The Last Decade

W. Brückl

24 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. Brückl Germany 10 198 163 56 53 52 27 329
Yi-Hong Ling China 10 123 0.6× 120 0.7× 59 1.1× 47 0.9× 87 1.7× 12 333
Kunli Zhu China 13 233 1.2× 97 0.6× 35 0.6× 49 0.9× 55 1.1× 28 342
Nishan H. Fernando United States 9 259 1.3× 142 0.9× 35 0.6× 43 0.8× 84 1.6× 13 390
Luca Tondulli Italy 9 174 0.9× 114 0.7× 36 0.6× 33 0.6× 44 0.8× 14 285
Gökçe Aşkan United States 10 193 1.0× 105 0.6× 39 0.7× 32 0.6× 64 1.2× 18 356
Loretta D’Onofrio Italy 8 137 0.7× 80 0.5× 23 0.4× 93 1.8× 60 1.2× 18 299
Nikoletta Sidiropoulos United States 8 163 0.8× 114 0.7× 33 0.6× 51 1.0× 76 1.5× 21 336
Kristen K. Ciombor United States 10 191 1.0× 78 0.5× 25 0.4× 30 0.6× 84 1.6× 26 315
Kouichiro Tsugawa Japan 10 196 1.0× 173 1.1× 61 1.1× 42 0.8× 94 1.8× 19 476
Ondřej Kubeček Czechia 8 171 0.9× 101 0.6× 41 0.7× 16 0.3× 60 1.2× 31 339

Countries citing papers authored by W. Brückl

Since Specialization
Citations

This map shows the geographic impact of W. Brückl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Brückl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Brückl more than expected).

Fields of papers citing papers by W. Brückl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Brückl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Brückl. The network helps show where W. Brückl may publish in the future.

Co-authorship network of co-authors of W. Brückl

This figure shows the co-authorship network connecting the top 25 collaborators of W. Brückl. A scholar is included among the top collaborators of W. Brückl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Brückl. W. Brückl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bleckmann, Annalen, et al.. (2022). Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. Journal of Cancer Research and Clinical Oncology. 149(4). 1495–1511. 23 indexed citations
2.
Brückl, W., Martin Reck, Frank Griesinger, et al.. (2021). Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. Therapeutic Advances in Medical Oncology. 13. 4277424393–4277424393. 10 indexed citations
3.
4.
Faehling, Martin, Christian Schumann, Petros Christopoulos, et al.. (2020). Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP. SHILAP Revista de lepidopterología. 34. 106556–106556. 3 indexed citations
5.
6.
Brückl, W., et al.. (2019). P2.01-79 Afatinib in EGFR Mutation-Positive (EGFRm+) NSCLC Harbouring Uncommon Mutations: Experience in ‘Real-World’ Clinical Practice. Journal of Thoracic Oncology. 14(10). S670–S671. 2 indexed citations
7.
8.
Brückl, W., Joachim H. Ficker, Markus Tiemann, et al.. (2018). Empfehlung der Sektionen 2 und 11 der DGP zur Rebiopsie bei Lungenkarzinomen. Pneumologie. 72(9). 617–623.
9.
Brückl, W., Amanda Tufman, & Rudolf M. Huber. (2016). Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. Expert Review of Anticancer Therapy. 17(2). 143–155. 25 indexed citations
10.
11.
Brückl, W., Gerald Wiest, & Joachim H. Ficker. (2010). Aktueller Stellenwert von Erlotinib und Gefitinib in der palliativen Therapie des NSCLC – welche Bedeutung hat der EGF-R-Mutationsstatus?. Pneumologie. 64(12). 727–735. 2 indexed citations
12.
Meyer, Alexander, Susanne Merkel, W. Brückl, et al.. (2009). Cdc2 as prognostic marker in stage UICC II colon carcinomas. European Journal of Cancer. 45(8). 1466–1473. 18 indexed citations
13.
Wein, A., Christian U. Riedel, W. Brückl, et al.. (2008). Verbesserungen der palliativen Behandlung des kolorektalen Karzinoms. DMW - Deutsche Medizinische Wochenschrift. 125(5). 121–125.
14.
Brückl, W., et al.. (2008). Medikamentöse Therapie des kleinzelligen Bronchialkarzinoms (SCLC) - neue molekulare Therapieansätze. Pneumologie. 62(1). 23–30. 1 indexed citations
15.
Croner, Roland S., W. Brückl, Franz Rödel, et al.. (2008). Molecular Signature for Lymphatic Metastasis in Colorectal Carcinomas. Annals of Surgery. 247(5). 803–810. 29 indexed citations
16.
17.
Wehrhan, Falk, Franz Rödel, Gerhard G. Grabenbauer, et al.. (2004). Transforming growth factor beta 1 dependent regulation of Tenascin-C in radiation impaired wound healing. Radiotherapy and Oncology. 72(3). 297–303. 29 indexed citations
18.
19.
Bittorf, Birgit, Hermann Keßler, Susanne Merkel, et al.. (2001). Multiple primary malignancies: An epidemiological and pedigree analysis of 57 patients with at least three tumours. European Journal of Surgical Oncology. 27(3). 302–313. 47 indexed citations
20.
Wein, A., Christian U. Riedel, W. Brückl, et al.. (2001). Weekly 24-h infusion of high-dose 5-Fluorouracil (5-FU) with folinic acid (FA) in adjuvant therapy of colon cancer. Zeitschrift für Gastroenterologie. 39(2). 153–156. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yi-Hong Ling Breakdown of academic impact, for papers by Kunli Zhu Breakdown of academic impact, for papers by Nishan H. Fernando Breakdown of academic impact, for papers by Luca Tondulli Breakdown of academic impact, for papers by Gökçe Aşkan Breakdown of academic impact, for papers by Loretta D’Onofrio Breakdown of academic impact, for papers by Nikoletta Sidiropoulos Breakdown of academic impact, for papers by Kristen K. Ciombor Breakdown of academic impact, for papers by Kouichiro Tsugawa Breakdown of academic impact, for papers by Ondřej Kubeček
Rankless by CCL
2026